Colgate-Palmolive (NYSE: CL) reported fourth-quarter earnings and revenue that exceeded expectations, even as the company recorded a sizable impairment charge tied to its skin health business. Shares rose more than 4% intraday.
Colgate posted adjusted earnings per share of $0.95, beating analyst estimates of $0.91. Revenue reached $5.23 billion, topping consensus forecasts of $5.12 billion and rising 5.8% year over year. Organic sales increased 2.2%, excluding currency impacts and acquisitions.
The results came despite a non-cash, after-tax impairment charge of $794 million related to goodwill and intangible assets in the company’s skin health business, primarily Filorga. As a result, Colgate reported a GAAP loss of $0.05 per share for the quarter.
Latin America delivered particularly strong performance, with reported sales rising 12.8% and organic growth of 6.5%. The Africa/Eurasia region also posted robust gains, with reported sales up 15% and organic growth of 10.3%.
For full-year 2025, Colgate reported net sales of $20.38 billion, up 1.4% from 2024, while adjusted earnings per share increased 3% to $3.69.
Looking ahead to 2026, the company projected net sales growth of 2% to 6%, including a low-single-digit benefit from foreign exchange. Organic sales were expected to rise 1% to 4%. On a non-GAAP basis, Colgate forecast gross margin expansion, higher advertising investment, and low- to mid-single-digit EPS growth.
